This review summarizes approaches to define appropriate LAAs as targets of a T-cell-based vaccine immunotherapy. Current clinical LAA peptide vaccination protocols targeting Wilms' tumor gene ...

These peptides (T-cell epitopes) are more diverse than originally thought. Vaccine design must take into account both chemical modifications to antigens and heterogeneous length of these important ...

The field of vaccinology is being transformed by peptide science, enabling more precise and personalized approaches to both preventive and therapeutic vaccines. Synthetic peptide antigens can be ...

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer Research and Director of the Vaccine and Cell Therapy Laboratory, have tested ...

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

Peptide-based vaccines deliver tumor-specific antigens to dendritic cells (DCs), triggering tumor-targeted T-cell responses. A peptide-peptide conjugate technology previously developed by researchers ...

Greenwich Lifesciences Inc. followed a February update with another on the phase III Flamingo-01 trial, providing open-label immune response data for GLSI-100, a HER2/neu peptide vaccine immunotherapy ...

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.